Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 18, Issue 2, 2016, Pages 159-168

  Ilag, L L ^a   Deeg, M A ^a   Costigan, T ^a   Hollander, P ^b   Blevins, T C ^c   Edelman, S V ^d   Konrad, R J ^a   Ortmann, R A ^a   Pollom, R K ^a   Huster, W J ^a   Zielonka, J S ^a   Prince, M J ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Baylor Endocrine Center   (United States)

^c Texas Diabetes and Endocrinology   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biosimilar insulin; Insulin antibody; Insulin glargine; LY2963016 insulin glargine

Indexed keywords

INSULIN ANTIBODY; INSULIN GLARGINE; ANTIDIABETIC AGENT; BIOSIMILAR AGENT; HUMAN INSULIN; LY2963016 INSULIN GLARGINE; RECOMBINANT PROTEIN;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; TREATMENT DURATION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; ASYMPTOMATIC DISEASES; BLOOD; CHEMICALLY INDUCED; COMPLICATION; CROSS REACTION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; DRUG HYPERSENSITIVITY; GENETICS; HYPERGLYCEMIA; HYPOGLYCEMIA; IMMUNOGENETICS; IMMUNOLOGY; INCIDENCE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ASYMPTOMATIC DISEASES; BIOSIMILAR PHARMACEUTICALS; CROSS REACTIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG HYPERSENSITIVITY; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; IMMUNOGENETIC PHENOMENA; INCIDENCE; INSULIN ANTIBODIES; INSULIN GLARGINE; INSULIN, REGULAR, HUMAN; RECOMBINANT PROTEINS;

EID: 84956873259     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12584     Document Type: Article

References (16)

1. European Medicines Agency. Abasaglar. 2014. Available from URL: http://www.ema.europa.eu/ema/index.jsp?curl=⃥pages/medicines/human/medicines/002835/human_med_001790.jsp=⃥mid=⃥WC0b01ac058001d124. Accessed 28 April 2015.
2. Eli Lilly and Company Press Release. European Commission grants Lilly and Boehringer Ingelheim's insulin glargine product marketing authorisation in Europe. 2014. Available from URL: http://lilly.mediaroom.com/index.php?s=⃥9042=⃥item=⃥137348. Accessed 18 May 2015.
3. Blevins TC, Dahl D, Rosenstock J etal. Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomised controlled trial (The ELEMENT 1 Study). Diabetes Obes Metab 2015; 17: 726-733.
4. Rosenstock J, Hollander P, Bhargava A etal. Similar efficacy and safety with LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double blind controlled trial (the ELEMENT 2 study). Diabetes Obes Metab 2015; 17: 734-741.
5. European Medicines Agency. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues. 2015. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/03/WC500184161.pdf. Accessed 29 April 2015.
6. Food and Drug Administration. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. 2015. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Accessed 16 April 2015.
7. European Medicines Agency. Committee for Medicinal Products for Human Use. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Guidance on similar medicinal products containing recombinant human soluble insulin. EMEA/CHMP/BMWP/32775/2005. London, 22 February 2006. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003957.pdf. Accessed 28 April 2015.
8. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997; 277: 925-926.
9. Food and Drug Administration. Guidance for industry assay development for immunogenicity testing of therapeutic proteins. Draft guidance. 2009. Available from URL: http://www.fda.gov/downloads/Drugs/.../Guidances/UCM192750.pdf. Accessed 16 December 2014.
10. Shankar G, Arkin S, Cocea L etal. Assessment and reporting of clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J 2014; 16: 658-673.
11. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2000; 23: 639-643.
12. Lindholm A, Jensen LB, Home PD, Raskin P, Boehm BO, Råstam J. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care 2002; 25: 876-882.
13. Zinman B, Philis-Tsimikas A, Cariou B etal. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 2012; 35: 2464-2471.
14. Centers for Disease Control and Prevention. National diabetes fact sheet. 2011. Available from URL: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed 29 April 2015.
15. Fineberg SE, Kawabata TT, Finco-Kent D, Fountaine RJ, Finch GL, Krasner AS. Immunological responses to exogenous insulin. Endocr Rev 2007; 28: 625-652.
16. Eibl N, Spatz M, Fischer GF etal. Impaired primary immune response in type-1 diabetes: results from a controlled vaccination study. Clin Immunol 2002; 103: 249-259.